BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 28600647)

  • 1. Hybrid
    Goorts B; Vöö S; van Nijnatten TJA; Kooreman LFS; de Boer M; Keymeulen KBMI; Aarnoutse R; Wildberger JE; Mottaghy FM; Lobbes MBI; Smidt ML
    Eur J Nucl Med Mol Imaging; 2017 Oct; 44(11):1796-1805. PubMed ID: 28600647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy.
    Koolen BB; Valdés Olmos RA; Elkhuizen PH; Vogel WV; Vrancken Peeters MJ; Rodenhuis S; Rutgers EJ
    Breast Cancer Res Treat; 2012 Aug; 135(1):231-40. PubMed ID: 22872522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Pretreatment Combined (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging on Radiation Therapy Treatment Decisions in Locally Advanced Breast Cancer.
    Ng SP; David S; Alamgeer M; Ganju V
    Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):111-7. PubMed ID: 26279029
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of
    Kirchner J; Martin O; Umutlu L; Herrmann K; Bittner AK; Hoffmann O; Mohrmann S; Gauler T; Theurer S; Antke C; Esposito I; Kinner S; Schaarschmidt BM; Kowall B; Lütke-Brintrup D; Stang A; Becker AS; Antoch G; Buchbender C
    Eur J Radiol; 2020 Jul; 128():108975. PubMed ID: 32371185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer staging in a single session: whole-body PET/CT mammography.
    Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G
    J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical utility of 18F-FDG-PET/MR for preoperative breast cancer staging.
    Botsikas D; Kalovidouri A; Becker M; Copercini M; Djema DA; Bodmer A; Monnier S; Becker CD; Montet X; Delattre BM; Ratib O; Garibotto V; Tabouret-Viaud C
    Eur Radiol; 2016 Jul; 26(7):2297-307. PubMed ID: 26477029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
    Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
    Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
    Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
    J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prone Versus Supine Breast FDG-PET/CT for Assessing Locoregional Disease Distribution in Locally Advanced Breast Cancer.
    Abramson RG; Lambert KF; Jones-Jackson LB; Arlinghaus LR; Williams J; Abramson VG; Chakravarthy AB; Yankeelov TE
    Acad Radiol; 2015 Jul; 22(7):853-9. PubMed ID: 25865435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of Advanced Axillary Lymph Node Metastases (ypN2-3) Using Breast MR imaging and PET/CT after Neoadjuvant Chemotherapy in Invasive Ductal Carcinoma Patients.
    Kim WH; Lee SW; Kim HJ; Chae YS; Jeong SY; Jung JH; Park HY; Lee WK
    Sci Rep; 2018 Feb; 8(1):3181. PubMed ID: 29453385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.
    Koolen BB; Valdés Olmos RA; Wesseling J; Vogel WV; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Vrancken Peeters MJ
    Ann Surg Oncol; 2013 Jul; 20(7):2227-35. PubMed ID: 23456316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of (18)F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited.
    Zhang X; Wu F; Han P
    Hell J Nucl Med; 2014; 17(3):177-83. PubMed ID: 25526754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Groheux D; Giacchetti S; Delord M; de Roquancourt A; Merlet P; Hamy AS; Espié M; Hindié E
    Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):377-85. PubMed ID: 25432784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of lymph node status after neoadjuvant chemotherapy in breast cancer patients: comparison of diagnostic performance of ultrasound, MRI and ¹⁸F-FDG PET/CT.
    You S; Kang DK; Jung YS; An YS; Jeon GS; Kim TH
    Br J Radiol; 2015 Aug; 88(1052):20150143. PubMed ID: 26110204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphoscintigraphy in breast cancer patients after neoadjuvant chemotherapy. Diagnostic value and the work-up of sentinel node negative patients.
    Dalus K; Reitsamer R; Holzmannhofer J; Rendl G; Pirich C; Kronberger C; Rettenbacher L
    Nuklearmedizin; 2011; 50(1):33-8. PubMed ID: 21336417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential impact of 18F-FDG PET/CT on patients selection for neoadjuvant chemotherapy before radical cystectomy.
    Rouanne M; Girma A; Neuzillet Y; Vilain D; Radulescu C; Letang N; Yonneau L; Hervé JM; Botto H; Le Stanc E; Lebret T
    Eur J Surg Oncol; 2014 Dec; 40(12):1724-30. PubMed ID: 25242381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers.
    Gaeta CM; Vercher-Conejero JL; Sher AC; Kohan A; Rubbert C; Avril N
    Q J Nucl Med Mol Imaging; 2013 Dec; 57(4):352-66. PubMed ID: 24322792
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    Salminen A; Jambor I; Merisaari H; Ettala O; Virtanen J; Koskinen I; Veskimae E; Sairanen J; Taimen P; Kemppainen J; Minn H; Boström PJ
    Cancer Imaging; 2018 Aug; 18(1):25. PubMed ID: 30068379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous whole-body ¹⁸F-FDG PET-MRI in primary staging of breast cancer: a pilot study.
    Taneja S; Jena A; Goel R; Sarin R; Kaul S
    Eur J Radiol; 2014 Dec; 83(12):2231-2239. PubMed ID: 25282709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of (18)F-FDG PET/CT and MRI in Assessing Pathological Complete Response to Neoadjuvant Chemotherapy in Patients with Breast Cancer: A Systematic Review and Meta-Analysis.
    Liu Q; Wang C; Li P; Liu J; Huang G; Song S
    Biomed Res Int; 2016; 2016():3746232. PubMed ID: 26981529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.